Eris Lifesciences consolidates its stake in Swiss Parenterals
The proposed transaction will be effected as a share swap
The proposed transaction will be effected as a share swap
These certifications reflect the company's continuous commitment to maintaining international standards of environmental sustainability as well as occupational health and safety
The company will soon be launching a new portfolio of products in this segment
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
The partnership will enable rapid and reliable product delivery
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
The formulation is backed by over 80 clinical trials and 200 scientific publications
Subscribe To Our Newsletter & Stay Updated